|
Efficacy of imiquimod in the management of lentigo maligna. |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Pierre Fabre; Roche/Genentech |
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - MSD Oncology; Pierre Fabre |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Speakers' Bureau - MSD Oncology |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Novartis |
|
|
Consulting or Advisory Role - AstraZeneca |
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche Molecular Diagnostics; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech |